SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA ($NVDA) is trending due to multiple partnerships and product announcements driving optimism around its role in AI, autonomous vehicles, and 6G. Community discussions highlight the company's potential for continued revenue growth and market dominance. Recent news includes collaborations with Palantir, Uber, and Nokia, as well as updates on Blackwell GPU production and supercomputer projects.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is trending due to a recently announced $5 billion partnership with Brookfield to power AI data centers, driving investor optimism and discussions about the company's role in meeting the increasing energy demands of AI. The community is analyzing the potential long-term impact of this deal, with some highlighting the company's strong position in the energy sector and others questioning the current valuation. This surge comes amid a broader conversation about the energy needs of AI and the potential for alternative power solutions.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle ($ORCL) is trending due to its involvement in AI infrastructure projects, particularly related to NVIDIA and the Department of Energy. The community is discussing Oracle's potential to reach a $1T market cap and its role in partnerships with companies like Uber and Eli Lilly. Despite positive news, some traders express frustration with the stock's recent performance, citing a high debt ratio.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nvidia's recent $1 billion investment in Nokia to advance AI-driven 5G and 6G technology is driving significant interest in the stock. Community discussions revolve around the potential for a short squeeze and Nokia's renewed relevance in the AI and telecom landscape, with some seeing parallels to past meme stock rallies.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to its strong connection to the AI infrastructure boom and recent news highlighting collaborations with NVIDIA, Intel, and Micron, driving optimism about future growth. Community discussions revolve around Supermicro's potential to capitalize on increasing AI demand, with debates on whether the recent dip presents a buying opportunity or signals deeper issues. Investors are closely watching for news of a CFO hire and the upcoming earnings report, anticipating further details on the company's strategic direction and financial performance.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft ($MSFT) is trending as investors discuss its AI strategy, particularly its stake in OpenAI and the potential for further gains in cloud revenue. The community is weighing the impact of these factors on upcoming earnings, with some anticipating a run to \$600, while others are focused on technical indicators and potential breakout levels. Broader market sentiment and the tech sector's overall health are also influencing the conversation around MSFT.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors closely monitor the EMA's decision on Blarcamesine, its Alzheimer's drug, with community chatter focused on potential approval outcomes and a possible short squeeze. Discussions also involve opinions on the drug's commercial viability and the impact of recent analyst reports, with some suggesting coordinated efforts to suppress the stock price.  The EMA decision is a key catalyst for the stock as the community weighs the potential for approval.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending amid discussions around its autonomous vehicle strategy, particularly its partnership with NVIDIA to deploy robotaxis by 2027. Community talking points include the competitive landscape with Tesla and potential impacts from new AI integrations, as well as debate over the company's valuation and long-term growth prospects in the evolving transportation sector.

THE TIME HAS COME TO FORM AN ALLIANCE TO TAKE OVER THE MEMESPACE, THE CRYPTO CABAL, AND THE WORLD PROPAGANDA MACHINE. WELCOME TO THE MEME ECONOMIC FORUM $MEF. THE MEME ECONOMIC FORUM (MEF) WILL SOON FLIP THE WORLD ECONOMIC FORUM (WEF). YOU WILL OWN MEMES AND YOU WILL BE HAPPY IS OUR SLOGAN.  FOR NOW, THERE IS NO UTILITY FOR WE ARE A MEME COIN. THANK YOU FOR YOUR CONSIDERATION.

Meme Economic Forum

Meme Economic Forum ($MEF) is trending, with community members highlighting its potential for momentum and profits. Discussions revolve around its chart structure and accumulation phase, as well as how to purchase it. The crypto is associated with bullish sentiment within the meme coin sector.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending due to discussions around recent earnings, forward guidance, and overall valuation, with community members debating whether the stock is oversold or a gift at current prices. The company's growth potential in the clean energy sector, particularly with new product launches, is also a key talking point, alongside concerns about macro headwinds and potential impacts from changes in solar incentives. Community members are actively weighing whether to buy the dip, await further price declines, or consider activist investor scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong results from the Phase 3 Summit trial of bezuclastinib in non-advanced systemic mastocytosis (NonAdvSM).The Summit Part 2 trial met its primary endpoint with a statistically significant placebo-adjusted improvement of 8.91 points in total symptom score (TSS) at 24 weeks.&nbsp;Patients treated with bezuclastinib saw a mean TSS reduction of 24.3 points, compared to 15.4 points for placebo.&nbsp;The drug also met all key secondary endpoints, including reductions in serum tryptase, with 87.4% of treated patients achieving at least a 50% drop versus none in the control group.&nbsp;Most adverse events were low-grade. Discontinuations due to side effects occurred in 5.9% of patients, all of whom recovered.H.C. Wainwright raised its price target to $22 from $12 and maintained a 'Buy' rating, raising its approval probability estimate to 95% from 60%, calling bezuclastinib a potential new standard of care.&nbsp;Jefferies lifted its target to $28 from $23 with a 'Buy' rating, citing a “home run” outcome and a $1 billion market opportunity in ISM alone.Leerink increased its target to $18 from $16 and reiterated an 'Outperform' rating, noting the safety profile exceeded expectations and pointing to strong positioning ahead of the Peak and Apex trial readouts due later in 2025.&nbsp;Baird took a more conservative view, raising its target to $9 from $7 while maintaining a 'Neutral' rating, stating that the results were better than the worst-case scenario but fell short of the best.Cogent remains on track to submit a new drug application (NDA) for bezuclastinib by year-end 2025 and will present detailed Summit findings at a medical conference later this year.Separately, Cogent announced a proposed public offering of $150 million in common stock.&nbsp;The company said proceeds will support continued development, regulatory and commercial preparation for bezuclastinib and other pipeline candidates, as well as general corporate purposes.&nbsp;On Stocktwits, retail sentiment for Cogent was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/COGT">Cogent’s stock</a> has risen 25.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Multiple firms raised their price targets on Cogent Biosciences (COGT) following strong results from the Phase 3 Summit trial of bezuclastinib/Photo credit: Getty Images

Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Equity

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options

Investors eyeing a purchase of Cogent Biosciences Inc (COGT) stock, but tentative about paying the going market price of 6.62/share, might benefit from considering selling puts among the...

Cogent Biosciences (COGT, $6.9) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that COGT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Cogent Biosciences (COGT, $6.9) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that COGT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Cogent Biosciences files to sell 31.2M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cogent Biosciences (COGT, $6.72) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling COGT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Cogent Biosciences (COGT, $6.72) Stochastic Oscillator left the oversold zone on March 28, 2024

This is a signal that COGT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.52	--	--	N/A
Q2 '25	-$0.59	--	--	N/A
Q1 '25	-$0.60	-$0.64	-5.48%	MISSED
Q4 '24	-$0.60	--	--	N/A
Q3 '24	-$0.57	-$0.64	-13.04%	MISSED

COGT
Cogent Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest COGT News

COGTCogent Biosciences Inc